Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

not_yet_recruiting150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_1

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT03128996
not_yet_recruitingphase_2

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

NCT07214064

Clinical Trials (2)

Showing 2 of 2 trials
NCT03128996Phase 1

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Recruiting
NCT07214064Phase 2

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2